WordNet
- a substance that exerts some force or effect
- a businessman who buys or sells for another in exchange for a commission (同)factor, broker
- any agent or representative of a federal agency or bureau (同)federal agent
- a representative who acts on behalf of other persons or organizations
- an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
- how long something has existed; "it was replaced because of its age"
- a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
- begin to seem older; get older; "The death of his wife caused him to age fast"
- make older; "The death of his child aged him tremendously"
- the work of inquiring into something thoroughly and systematically (同)investigating
PrepTutorEJDIC
- 『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
- 〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる
- (…の)『調査』,取り調べ,研究《+『of』(『into』)+『名』》
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 免疫調節および抗線維化による全身性硬化症（強皮症）治療 immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis scleroderma
- 2. 原発性骨髄線維症の予後および治療 prognosis and treatment of primary myelofibrosis
- 3. HIV感染患者におけるミトコンドリア毒性の治療および予防 treatment and prevention of mitochondrial toxicity in hiv infected patients
- 4. 成人における季節性インフルエンザの治療 treatment of seasonal influenza in adults
- 5. 造血細胞移植レシピエントにおける感染予防 prophylaxis of infections in hematopoietic cell transplant recipients
English Journal
- Investigational drugs for pruritus.
- Benecke H, Lotts T, Ständer S.SourceUniversity Medicine Göttingen, Center Nanoscale Microscopy and Molecular Physiology of the Brain , Humboldtallee 23, 37073 Göttingen , Germany.
- Expert opinion on investigational drugs.Expert Opin Investig Drugs.2013 Sep;22(9):1167-79. doi: 10.1517/13543784.2013.813932. Epub 2013 Jul 2.
- Introduction: Chronic pruritus (CP), defined as itch lasting for > 6 weeks, is a burdensome symptom of several different diseases, dermatological and systemic, with a high negative impact on the quality of life of patients. Given the manifold aetiologies of CP, therapy is often difficult. In rece
- PMID 23815605
- Investigational cytokine-targeted therapies for ulcerative colitis.
- Monteleone G, Pallone F, Caprioli F.SourceUniversity of Rome "Tor Vergata", Department of Systems Medicine , Via Montpellier 1, Rome, 00133 , Italy +39 06 72596158 ; +39 06 72596391 ; Gi.Monteleone@Med.uniroma2.it.
- Expert opinion on investigational drugs.Expert Opin Investig Drugs.2013 Sep;22(9):1123-32. doi: 10.1517/13543784.2013.813931. Epub 2013 Jun 27.
- Introduction: Up to one-third of patients with ulcerative colitis (UC) do not respond to standard medications, including mesalamine, steroids and thiopurines. The recognition that UC-related pathological process is the result of an altered balance between inflammatory and counter-regulatory signals,
- PMID 23802627
- A "Glucose Eater" Drug as a Therapeutic Agent in Psychiatry.
- Howland RH.AbstractMetformin, currently approved for the treatment of type 2 diabetes, is an interesting drug that has various cellular and molecular mechanisms. These mechanisms have justified other off-label clinical and investigational uses for diabetes prevention in high-risk patients, for polycystic ovary syndrome, non-diabetic obesity, non-alcoholic fatty liver disease, and for prevention or treatment of cancer. A large number of controlled and uncontrolled studies have generally found metformin to be effective, well tolerated, and safe for preventing or treating antipsychotic-related weight gain and for improving metabolic abnormalities in psychiatric patient populations. Metformin has the potential effect of inducing hippocampal neurogenesis, and additional studies of this drug are warranted in patients with mood or cognitive disorders. [Journal of Psychosocial Nursing and Mental Health Services, xx(x), xx-xx.].
- Journal of psychosocial nursing and mental health services.J Psychosoc Nurs Ment Health Serv.2013 Aug 16:1-4. doi: 10.3928/02793695-20130805-01. [Epub ahead of print]
- Metformin, currently approved for the treatment of type 2 diabetes, is an interesting drug that has various cellular and molecular mechanisms. These mechanisms have justified other off-label clinical and investigational uses for diabetes prevention in high-risk patients, for polycystic ovary syndrom
- PMID 23938069
Japanese Journal
- プラセボ対照無作為化試験による亜鉛欠乏性または特発性味覚障害219例に対するポラプレジンク投与の臨床的検討
- 池田 稔,黒野 祐一,井之口 昭 [他],武田 憲昭,愛場 庸雅,野村 泰之,阪上 雅史
- 日本耳鼻咽喉科學會會報 116(1), 17-26, 2013-01-20
- 味覚障害は, その評価において患者の自覚的な訴えに頼らざるを得ず, 現在もさらなるエビデンスの集積が求められている診断・治療の難しい疾患である. 今回われわれは亜鉛欠乏性または特発性に分類される味覚障害患者219例を対象に, ポラプレジンクを用いた亜鉛補充治療の効果をプラセボコントロールの無作為化二重盲検法により検討し, さらに背景データ等による詳細な検討を加えた. その結果, 亜鉛群は投与8週時 …
- NAID 10031145266
- 歯周炎罹患歯に対するFGF-2投与の長期的効果および安全性の検討
- 北村 正博,古市 保志,藤井 健男,川浪 雅光,國松 和司,島内 英俊,山田 了,小方 頼昌,和泉 雄一,伊藤 公一,中川 種昭,新井 高,山崎 和久,吉江 弘正,野口 俊英,渋谷 俊昭,高柴 正悟,栗原 英見,永田 俊彦,横田 誠,前田 勝正,廣藤 卓雄,坂上 竜資,原 宜興,野口 和行,小笠原 健文,村上 伸也
- 日本歯周病学会会誌 54(1), 38-45, 2012-03-28
- 塩基性線維芽細胞増殖因子（FGF-2：basic fibroblast growth factor）は，歯周組織再生誘導薬の有力なの一つと期待されており，動物実験および臨床治験によって，その有効性と安全性が明らかにされている。では，KCB-1D（歯周病を対象とした遺伝子組み換えヒト型 FGF-2 の治験薬コード）を用いた探索的第 II 臨床治験に参加した 79 名の被験者を対象として，フラップ手術 …
- NAID 10030555232
- 前臨床から臨床評価へのステージアップ (第8回抗悪性腫瘍薬開発フォーラム「明日のがん治療を目指して」)
- 村上 雅義
- 腫瘍内科 5(5), 539-543, 2010-05
- NAID 40017175601
Related Links
- Gaboxadol is a direct-acting gamma-amino butyric acid (GABA)A agonist under development by Danish pharmaceutical company Lundbeck for the treatment of sleep disorders. It has a different mode of action from benzodiazepine ...
- RECEIVING AND STORING THE INVESTIGATIONAL AGENT: RECEIVING AND STORING THE INVESTIGATIONAL AGENT The pharmacy is usually the best-qualified department in an institution to receive and store study drug, but ...
Related Pictures
★リンクテーブル★
| リンク元 | 「IND」「治験薬」「investigational drug」「investigational new drug」 |
| 関連記事 | 「agent」「investigational」「age」「investigation」 |
「IND」
- 治験薬 investigational new drug、investigational agent、investigational drug、、Investigational New Drug application
- インドメタシン
「治験薬」
「investigational drug」
「investigational new drug」
「agent」
- n.
- 代行者、代理人。代理業者
- 政府職員、官吏
- ある後位をする人、ある作用をするもの。動員、動力因、作用因。(文法)動作主。科学的変化を起こさせるもの、薬品、～剤。病原体
- 関
- agonist、agonistic、attorney、delegate、drug、etiologic agent、fomes、fomites、mediator、pathogen、pathogenic、pharmaceutical preparation、vector、vehicle
「investigational」
- adj.
- 研究の、調査の、治験の
- 関
- clinical research、clinical study、clinical test、clinical trial、examine、exploration、explore、inquire、inquiry、investigate、investigation、investigative、laboratory research、probing、research、scan、study、surveillance、survey、trial、work
「age」
- n.
- 年齢、歳
- v.
- 加齢する、熟成する
「investigation」
- n.
- 調査(of, into)、取り調べ、研究。研究論文、調査報告。
- 検査